GARDP is calling upon the global community to support its goal to develop and deliver five new treatments by 2025 in response to the growing burden of antibiotic resistant infections.

Alarming levels of resistance are now reported in countries of all income levels, with the result that hundreds of thousands of newborns are dying of untreatable sepsis, and patients are suffering from gonorrhoea and bloodstream infections that do not respond to any available antibiotics. Drug-resistant infections already cause at least 700,000 deaths globally each year.1 

 ‘5 BY 25’ is designed to contribute to tackle the issue of AMR. As an integral element of WHO’s Global Action Plan on AMR, GARDP is calling on Member States, philanthropic and other global organizations to support ‘5 BY 25’ and contribute towards its target of €500 million. This will allow GARDP to bring five new treatments that address the most urgent public health needs to patients.

The five new treatments will focus on the priority pathogens identified by WHO, and current unmet needs for diseases and key populations. This includes developing and delivering treatments for children, newborns with sepsis, and sexually-transmitted infections. See all five treatments needs and how GARDP will accomplish its ambition below:


While AMR has the highest burden in low to middle income countries, high income countries are also greatly affected. In fact, around 2.4 million people could die in high income countries between 2015 and 2050 without a sustained effort to contain AMR.2 Addressing AMR will be key to achieving Universal Health Coverage and meeting the Sustainable Development Goals.

Hear from some of our partners helping us develop and deliver ‘5 by 25′ around the world:



1. O’Neill, J. (Chair) (2016). Tackling drug-resistance globally: Final Report and recommendations.

2. Interagency coordination group on antimicrobial resistance (IACG). 2019. No time to wait: securing the future from drug-resistant infections.